/ MBX
MBX Biosciences Stock Skyrockets After Announcing Significant Phase 2 Results
MBX Biosciences stock soared 139% in premarket after positive Phase 2 results for its canvuparatide treatment.
September 22, 2025MBX Biosciences stock soared 139% in premarket after positive Phase 2 results for its canvuparatide treatment.
September 22, 2025